Urothelial Cancer

Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.

Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.

Guru P. Sonpavde, MD, provides commentary on several studies in urothelial carcinoma and how data presented at ESMO may affect clinical practice.

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Response to pembrolizumab monotherapy was observed regardless of prior response to chemotherapy in patients with advanced urothelial cancer.

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

The absence of POU2F2, may be predictive of response to maintenance avelumab in patients with advanced or metastatic urothelial carcinoma, according to findings from an analysis peripheral blood samples taken in the JAVELIN Bladder 100 trial.

Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Maintenance therapy with rucaparib following platinum-based chemotherapy prolonged progression-free survival compared with placebo in patients with DNA repair–deficient-positive, metastatic urothelial cancer.

The FDA has accepted for review a biologics license application for the IL-15 superagonist N-803 for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.